CIMAvax-EGF: A new therapeutic vaccine for advanced non-small cell lung cancer patients

Frontiers in Immunology

Volumn 8, Issue MAR, 2017, Pages

  Saavedra, Danay ^a   Crombet, Tania ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Cancer vaccine; CIMAvax EGF; Clinical trial; Immunotherapy; Non small cell lung cancer

Indexed keywords

AFATINIB; CANCER VACCINE; CARBOPLATIN; CIMAVAX EGF VACCINE; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; MONTANIDE ISA 51; PACLITAXEL; PEMBROLIZUMAB; UNCLASSIFIED DRUG; VINBLASTINE;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHILL; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FEVER; GENE OVEREXPRESSION; HEADACHE; HUMAN; IMMUNOGENICITY; MALAISE; MULTICENTER STUDY (TOPIC); NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR LOCALIZATION; VOMITING;

EID: 85017144575     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00269     Document Type: Review

References (37)

1. Fuge O, Vasdev N, Allchorne P, Green JS. Immunotherapy for bladder cancer. Res Rep Urol (2015) 7:65-79. doi:10.2147/RRU.S63447
2. Snyder A, Zamarin D, Wolchok JD. Immunotherapy of melanoma. Prog Tumor Res (2015) 42:22-9. doi:10.1159/000436998
3. Chee J, Robinson BW, Holt RA, Creaney J. Immunotherapy of lung malignancies-from gene sequencing to novel therapies. Chest (2016). doi:10.1016/j.chest.2016.10.007
4. Hughes PE, Caenepeel S, Wu LC. Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer. Trends Immunol (2016) 37(7):462-76. doi:10.1016/j.it.2016.04.010
5. Tsiatas M, Mountzios G, Curigliano G. Future perspectives in cancer immunotherapy. Ann Transl Med (2016) 4(14):273. doi:10.21037/atm.2016.07.14
6. Nicodemus CF. Antibody-based immunotherapy of solid cancers: progress and possibilities. Immunotherapy (2015) 7(8):923-39. doi:10.2217/imt.15.57
7. Jiang T, Zhou C. The past, present and future of immunotherapy against tumor. Transl Lung Cancer Res (2015) 4(3):253-64. doi:10.3978/j.issn.2218-6751.2015.01.06
8. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med (2015) 373(17):1627-39. doi:10.1056/NEJMoa1507643
9. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med (2015) 373(2):123-35. doi:10.1056/NEJMoa1504627
10. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (2016) 387(10027):1540-50. doi:10.1016/S0140-6736(15)01281-7
11. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med (2016) 375(19):1823-33. doi:10.1056/NEJMoa1606774
12. Romero D. Immunotherapy: atezolizumab becomes POPLAR. Nat Rev Clin Oncol (2016) 13(5):266. doi:10.1038/nrclinonc.2016.52
13. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. POPLAR Study Group. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, Phase 2 randomised controlled trial. Lancet (2016) 387(10030):1837-46. doi:10.1016/S0140-6736(16)00587-0
14. Tsuchida N, Murugan AK, Grieco M. Kirsten Ras* oncogene: significance of its discovery in human cancer research. Oncotarget (2016) 7(29):46717-33. doi:10.18632/oncotarget.8773
15. Mitsudomi T. Molecular epidemiology of lung cancer and geographic variations with special reference to EGFR mutations. Transl Lung Cancer Res (2014) 3(4):205-11. doi:10.3978/j.issn.2218-6751.2014.08.04
16. Nurwidya F, Takahashi F, Takahashi K. Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation. J Nat Sci Biol Med (2016) 7(2):119-23. doi:10.4103/0976-9668.184695
17. Socinski MA, Villaruz LC, Ross J. Understanding mechanisms of resistance in the epithelial growth factor receptor in non-small cell lung cancer and the role of biopsy at progression. Oncologist (2017) 22(1):3-11. doi:10.1634/theoncologist.2016-0285
18. Barron F, de la Torre-Vallejo M, Luna-Palencia RL, Cardona AF, Arrieta O. The safety of afatinib for the treatment of non-small cell lung cancer. Expert Opin Drug Saf (2016) 15(11):1563-72. doi:10.1080/14740338.2016.1236910
19. Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a Phase 2B, open-label, randomised controlled trial. Lancet Oncol (2016) 17(5):577-89. doi:10.1016/S1470-2045(16)30033-X
20. Singh B, Carpenter G, Coffey RJ. EGF receptor ligands: recent advances. F1000Res (2016) 5. doi:10.12688/f1000research.9025.1
21. Salazar R, Capellà G, Tabernero J. Paracrine network: another step in the complexity of resistance to EGFR blockade? Clin Cancer Res (2014) 20(24):6227-9. doi:10.1158/1078-0432.CCR-14-1615
22. Crombet Ramos T, Rodríguez PC, Neninger Vinageras E, Garcia Verdecia B, Lage Davila A. CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer. Expert Rev Vaccines (2015) 14(10):1303-11. doi:10.1586/14760584.2015.1079488
23. Rodríguez PC, Rodríguez G, González G, Lage A. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. MEDICC Rev (2010) 12(1):17-23.
24. García B, Neninger E, de la Torre A, Leonard I, Martínez R, Viada C, et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res (2008) 14(3):840-6. doi:10.1158/1078-0432.CCR-07-1050
25. Neninger E, de la Torre A, Osorio M, Catala M, Bravo I, Mendoza M, et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol (2008) 26(9):1452-9. doi:10.1200/JCO.2007.11.5980
26. Rodriguez PC, Popa X, Martínez O, Mendoza S, Santiesteban E, Crespo T, et al. A phase III clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res (2016) 22(15):3782-90. doi:10.1158/1078-0432.CCR-15-0855
27. Hasegawa T. Group sequential monitoring based on the weighted log-rank test statistic with the Fleming-Harrington class of weights in cancer vaccine studies. Pharm Stat (2016) 15(5):412-9. doi:10.1002/pst.1760
28. Cunningham AL, Garçon N, Leo O, Friedland LR, Strugnell R, Laupèze B. Vaccine development: from concept to early clinical testing. Vaccine (2016) 34(52):6655-64. doi:10.1016/j.vaccine.2016.10.016
29. Saavedra D. Immune response in long-term NSCLC survivors treated with CIMAvax-EGF vaccine. V International Workshop on CIMAvax-EGF. Abstract retrieved from Proceedings of the V International CIMAvax-EGF Workshop (Accession No. 4). Havana (2015).
30. Raaberg L, Nexø E, Jørgensen PE, Poulsen SS, Jakab M. Fetal effects of epidermal growth factor deficiency induced in rats by autoantibodies against epidermal growth factor. Pediatr Res (1995) 37:175. doi:10.1203/00006450-199502000-00009
31. Kelloff GJ, Sigman CC, Scher HI. Biomarker development in the context of urologic cancers. Urol Oncol (2015) 33(6):295-301. doi:10.1016/j.urolonc.2015.01.007
32. Chang S, Kohrt H, Maecker HT. Monitoring the immune competence of cancer patients to predict outcome. Cancer Immunol Immunother (2014) 63(7):713-9. doi:10.1007/s00262-014-1521-3
33. Saavedra D, García B, Lorenzo-Luaces P, González A, Popa X, Fuentes KP, et al. Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients. Cancer Immunol Immunother (2016) 65(1):37-45. doi:10.1007/s00262-015-1773-6
34. Neninger E, Verdecia BG, Crombet T, Viada C, Pereda S, Leonard I, et al. Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer. J Immunother (2009) 32(1):92-9. doi:10.1097/CJI.0b013e31818fe167
35. Fridlender ZG, Sun J, Singhal S, Kapoor V, Cheng G, Suzuki E, et al. Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. Mol Ther (2010) 18(11):1947-59. doi:10.1038/mt.2010.159
36. Di Blasio S, Wortel IM, van Bladel DA, de Vries LE, Duiveman-de Boer T, Worah K, et al. Human CD1c(+) DCs are critical cellular mediators of immune responses induced by immunogenic cell death. Oncoimmunology (2016) 5(8):e1192739. doi:10.1080/2162402X.2016.1192739
37. Castells Martínez EM, Del Valle R, González EC, Melchor A, Pérez PL, González I, et al. An enzyme immunoassay for determining epidermal growth factor (EGF) in human serum samples using an ultramicroanalytical system. J Immunoassay Immunochem (2016) 16:1-12. doi:10.1080/15321819.2016.1236729